Vaccine Could One Day Control High Blood Pressure

...pressure in hypertensive people," said vaccine inventor Martin Bachmann, of cytos Biotechnology in Schlieren, Switzerland. Currently, there are two probl...eart Association . SOURCES: Martin Bachmann, Ph.D., cytos Biotechnology, Schlieren, Switzerland; Gregg C. Fonarow, M.D., professor, c...

Blood Pressure Vaccine Shows Promise

...Juerg Nussberger, a professor of medicine at University Hospital of the Canton of Vaud in Lausanne, Switzerland. Nussberger also has an interest in cytos Biotechnology, which makes the vaccine. "The big hope is that you could give a few doses, and that would be it for life, then you wouldn't have som...

New Drug Could Keep High Blood Pressure Under Control for Several Months

...hat raises blood pressure by contracting vessels, by inducing antibodies. In the trial that involved 72 people, drug CYT006-AngQb developed by cytos Biotechnology reduced systolic blood pressure by 25 millimetres of mercury as compared to placebo treatment. The drug also lowered diastolic p...

New Vaccine to Control Blood Pressure

...0,000 deaths a year in Britain. It is currently treated with pills with side effects and some patients simply stop taking them. The Swiss firm cytos Biotechnology is also developing a similar vaccine that uses an empty virus shell to spur the immune system into action. ...

Now Single Jab Could Ward off Asthma, Eczema and Hay Fever

...ommon allergies such as asthma, eczema and hay fever. // The vaccine by cytos Biotechnology has been tested on humans and contains harmless DNA similar t...ad look quite spectacular. We think this is a one size fits all treatment," cytos chief executive Dr Wolfgang Renner said. It is hoped the single jab w...

Anti-allergy vaccine based on 'hygiene hypothesis'

...ars. As a result, the body begins to produce reactions against harmless substances like grass pollen. This theory was exploited by a Swiss-based cytos Biotechnology company to develop an anti-allergy drug that makes the immune system to focus on mycobacteria. This drug called CYT003 – QbG10 activates...

Effective Vaccine Found For Dust Mite Allergy

... symptoms such as sneezing, while asthmatics did not have frequent attacks. cytos is involved in developing anti-allergen vaccines and plans to move forward ...antihistamines and inhaled steroids, suppress symptoms temporarily. The cytos vaccine is thought to give a permanent cure as it consists of an empty viru...

Hope for Dust Mite Allergy Sufferers

... Swiss biotechnology company cytos has developed a vaccine for dust mite allergy sufferers.Dust mites found in...immune system, which tries to suppress that allergic reaction. According to cytos the benefits were found to persist even eight months after the inoculations...

Cytos in Medical Technology

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

...compared to placebo. Dr. Wolfgang Renner, CEO of cytos Biotechnology, commented: "These results mark a fu...therapy for a broad range of allergic diseases." cytos Biotechnology will host a conference call and Q&am...ents. Placebo: dummy medical treatment. QbG10: cytos Biotechnology’s Immunodrug™ Qb filled ...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

... cytos Biotechnology reports positive results from placeb... SCHLIEREN (Zurich), Switzerland, May 15, 2007 - cytos Biotechnology AG (SWX:CYTN) reported today positiv...tor of 10 p-value Dr. Wolfgang Renner, CEO of cytos Biotechnology commented: “With each study we...

Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis

...TTACHMENT FOR CHART Dr. Wolfgang Renner, CEO of cytos Biotechnology, commented the study results: &ldquo... "http://www.cytos.com/">www.cytos.com About cytos Biotechnology AG Cytos Biotechnology AG is a publ...he high flexibility of its ImmunodrugTM platform, cytos Biotechnology has built a pipeline of different Im...

CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007

...tis. Please feel free to contact us at the address below should you wish to receive further information, address questions, or arrange meetings with cytos Biotechnology directly. With best regards, Claudine Blaser For more information please contact: Claudine Blaser, PhD Director Corporate Commun...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

... to moderate hypertension. On January 26, 2007, cytos Biotechnology reported top-line data from this stu.... Philipp Müller, EVP Clinical Development at cytos Biotechnology comments on the study results: &l...body response induced by vaccination. About cytos Biotechnology AG Cytos Biotechnology AG is a publ...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

... SCHLIEREN (Zurich), Switzerland, July 3, 2007 - cytos Biotechnology AG (SWX:CYTN) announced today result...sted in this trial. Dr. Wolfgang Renner, CEO of cytos Biotechnology, commented: “While CYT003-QbG1...llergy. For further information please contact: cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schliere...

Cytos in Biological Technology

Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007

Oral Presentation by Prof. Juerg Nussberger, MD, Today at 9.45am (EST): "CYT006-AngQb, a Vaccine Against Hypertension Targeting Angiotensin II, Reduces Early-Morning and Day-Time Blood Pressure." The American Heart Association Publishes Today an Independent News Release ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...) ARPIDA AG (SWX, Switzerland: ARPN) BTG (London Main Market, U.K.: BGC) cytos BIOTECH AG (SWX, Switzerland: CYTN) GENMAB AS (OMX Nordic Exchange Copenha...C A/S (OMX Nordic Exchange Copenhagen: BAVA) CRUCELL-ADR (NASDAQ: CRXL ) cytos BIOTECHNOLOGY AG-REG (SWX, Switzerland: CYTN) ELAN CORP PLC-ADR (NYSE: EL...